FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for a pre-approval manufacturing inspection. Azurity partnership provides funding and commercialization support: The U.S. and Canada agreement includes $30 million in upfront and near-term milestone payments, more than $290 million in potential additional milestones, and tiered royalties.
Azurity expects to launch D-PLEX100 in early 2027 if approved. Financial position improved: PolyPid's second-quarter net loss narrowed to $7.8 million from $10 million a year earlier, while the subsequent Azurity payments strengthened liquidity and are expected to fund operations into 2028. PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
D-PLEX100 is being developed to prevent surgical site infections in patients undergoing abdominal corrective surgery. CEO Dikla Czaczkes Akselbrad said the FDA accepted the company's NDA for filing on July 27, after the company completed its submission during the second quarter. The agency granted priority review and set a Prescription Drug User Fee Act goal date of Nov. 28, 2026. → SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat Akselbrad said the FDA identified no filing review issues in the acceptance notice.
Priority review reduces the standard review timeline to six months from 10 months, according to the company. PolyPid expects an FDA pre-approval inspection of its manufacturing facility as part of the review process and continues to prepare for that inspection through mock audits and outside consultants. On July 17, PolyPid entered an exclusive agreement with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada.
PolyPid said it has secured $30 million in aggregate upfront and near-term milestone payments, consisting of a $15 million payment at signing and a further $15 million payment following FDA acceptance of the NDA. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be The agreement also provides PolyPid eligibility for more than $290 million in additional regulatory, launch and sales milestones. The company is entitled to tiered royalties on Azurity's net sales ranging from the mid-teens to mid-20s percentages. PolyPid will retain global manufacturing responsibility and will receive an agreed transfer price for each unit supplied to Azurity.
Chief Operating Officer Ori Warshavsky said Azurity was selected after a competitive partnering process involving multiple prospective commercial partners. He cited Azurity's portfolio of more than 50 medicines, its hospital and surgical-channel presence, and relationships with more than 1,700 hospitals and academic institutions as factors supporting the selection. → First Solar's Profit Engine Faces a New Policy Test in Washington Azurity will lead commercial activities including sales force development, national account planning, medical affairs and pharmacy-channel work. PolyPid will retain global regulatory strategy and manufacturing responsibilities.
Extract — continue reading at the source.
